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1. INTRODUCTION {#cam43119-sec-0006}
===============

Pancreatic cancer (PC) is associated with poor survival with a dismal 5‐year survival rate of only 7%.[^1^](#cam43119-bib-0001){ref-type="ref"} There was little significant progress in the treatment of PC during the past two decades.[^2^](#cam43119-bib-0002){ref-type="ref"}, [^3^](#cam43119-bib-0003){ref-type="ref"} Although surgery provides the best chance to obtain better survival, only 15% of patients were eligible candidates for surgery. More than half (55%) of patients have metastatic PC. Another 40% of patients were classified as locally advanced PC (LAPC), which were characterized with vascular involvement prohibiting upfront resection.[^4^](#cam43119-bib-0004){ref-type="ref"}, [^5^](#cam43119-bib-0005){ref-type="ref"}, [^6^](#cam43119-bib-0006){ref-type="ref"} There was no consensus on the most suitable treatment for patients with LAPC. The most frequently recommended treatment was chemotherapy and chemoradiotherapy, which only achieved modest survival benefit for patients with LAPC.[^7^](#cam43119-bib-0007){ref-type="ref"} The median overall survival (OS) was only 9‐12 months for LAPC patients treated with chemotherapy or chemoradiotherapy.[^8^](#cam43119-bib-0008){ref-type="ref"}, [^9^](#cam43119-bib-0009){ref-type="ref"}, [^10^](#cam43119-bib-0010){ref-type="ref"} In addition, it was shown that locally destructive disease was responsible for half of mortalities in patients with LAPC, although distant metastasis was found to be the most common form of disease progression,[^11^](#cam43119-bib-0011){ref-type="ref"} indicating the importance of local destructive therapies. Considering the limited success of current therapy for the local control of disease and prolonging survival of patients with LAPC, novel local destructive therapies have been tried and viewed as more and more important treatments.[^12^](#cam43119-bib-0012){ref-type="ref"}

Nowadays, new insights have been focused on some novel local therapies as new treatment options for LAPC, including radiofrequency ablation (RFA) and irreversible electroporation (IRE).[^13^](#cam43119-bib-0013){ref-type="ref"} Radiofrequency ablation has been applied in solid organ malignancies, such as renal carcinoma,[^14^](#cam43119-bib-0014){ref-type="ref"} hepatocellular carcinoma,[^15^](#cam43119-bib-0015){ref-type="ref"} and LAPC.[^16^](#cam43119-bib-0016){ref-type="ref"}, [^17^](#cam43119-bib-0017){ref-type="ref"}, [^18^](#cam43119-bib-0018){ref-type="ref"} Also, as a subsequent treatment after induction chemotherapy in LAPC, there were many studies illustrating the survival benefit of IRE.[^19^](#cam43119-bib-0019){ref-type="ref"}, [^20^](#cam43119-bib-0020){ref-type="ref"}, [^21^](#cam43119-bib-0021){ref-type="ref"} As a nonthermal method, IRE creates defects in cell membrane through the transmission of high‐voltage currents through the tumor, inducing loss of homeostasis and apoptotic death of tumor cells.[^21^](#cam43119-bib-0021){ref-type="ref"} However, there is only limited evidence of which ablation method is survival beneficial to the LAPC patients.[^22^](#cam43119-bib-0022){ref-type="ref"} Therefore, the primary aim of this study was the OS comparison and the secondary aim was the progression‐free survival (PFS) comparison in LAPC patients who received IRE and RFA after the induction chemotherapy.

2. METHODS {#cam43119-sec-0007}
==========

2.1. Patients {#cam43119-sec-0008}
-------------

Patients who were diagnosed with LAPC and had received IRE or RFA combined with induction chemotherapy from August 2015 to August 2017 at Sun Yat‐sen University Cancer Center were retrospectively reviewed. The diagnosis of LAPC and the final therapy were confirmed by a multidisciplinary team, which included specialized pancreatic surgeons, oncologists, pathologists, and radiologists. Patients who were pathologically confirmed pancreatic adenocarcinoma and radiologically confirmed LAPC were included into this study. Locally advanced pancreatic cancer was defined as the description of AJCC staging system for pancreatic cancer.[^23^](#cam43119-bib-0023){ref-type="ref"}, [^24^](#cam43119-bib-0024){ref-type="ref"} All LAPC patients had received four months of induction chemotherapy (FOLFIRINOX or Gem‐based chemotherapy)[^25^](#cam43119-bib-0025){ref-type="ref"} and those who were also judged as unresectable ones after induction chemotherapy were included in this study. A total of 378 patients were included into this study and 303 patients were excluded based on the following exclusion criteria: (a) second primary cancer; (b) distant metastases; (c) other treatments, such as surgical resection and radiotherapy; (d) a history of heart arrhythmia; and (e) missing or incomplete information. Finally, 75 patients were enrolled into this study. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and obtained approval from the Ethics Committee of Sun Yat‐sen University Cancer Center. Written informed consent was obtained from all patients.

2.2. Data and treatment procedure {#cam43119-sec-0009}
---------------------------------

The associated clinical data were retrieved and analyzed. Carbohydrate antigen 19‐9 (CA19‐9) and carcinoembryonic antigen (CEA) were taken after chemotherapy and prior to ablation. Before induction chemotherapy, which was conducted as the procedures described in our previous study,[^25^](#cam43119-bib-0025){ref-type="ref"} biopsy was finished for all patients and tumor grade was determined. After induction chemotherapy, as long as no metastases were detected, IRE or RFA was performed and the same line of chemotherapy was followed after IRE or RFA therapy. A diagnostic laparoscopy is adopted to confirm that no metastasis is present. If none is found, IRE or RFA is performed. As shown in our previous study,[^25^](#cam43119-bib-0025){ref-type="ref"} specialized pancreatic surgeons performed all IRE and RFA, which were performed using an open technique and guided by intraoperative ultrasound. The general anesthesia with deep neuromuscular block was adopted. In the procedure of IRE, under the guidance of ultrasound during surgery, 2 to 6 probes were adopted to create an electric field around the tumor, which caused nanoscale pore formation in the cell membrane. Also, the electrode of RFA was placed at the center of tumor. The ablation of IRE and RFA was monitored with ultrasound during surgery. The same line of chemotherapy was performed 7‐14 days after IRE treatment. According to the guidelines from National Comprehensive Cancer Network (NCCN),[^5^](#cam43119-bib-0005){ref-type="ref"} 4 cm was adopted as the cutoff value of tumor size in this study. Tumors which were larger than 4 cm were classified as large ones for pancreatic cancer. To further compare the efficacy of IRE and RFA in LAPC patients with large tumors, the survival comparisons of IRE and RFA were conducted in patients with tumors that are larger than 4 cm.

2.3. Follow‐up {#cam43119-sec-0010}
--------------

The follow‐up procedures, including hematological examination, such as CA19‐9 and CEA analysis, and radiological examination (abdominal CT or MRI) were regularly performed for patients, who had the first one at approximately 1 month after IRE or RFA and the following ones every 2‐3 months thereafter. OS and PFS were defined as the duration from the date of induction chemotherapy until death or disease progression. If no endpoint event was observed, the date of last follow‐up was also used to calculate OS or PFS. The last follow‐up was completed on September 30, 2018.

2.4. Propensity score matching (PSM) analysis {#cam43119-sec-0011}
---------------------------------------------

To minimize selection bias, PSM analysis was utilized based on the following factors: age, gender, tumor site, tumor size, tumor grade, TNM stage, CA19‐9, and CEA. A two‐to‐one nearest‐neighbor matching algorithm[^26^](#cam43119-bib-0026){ref-type="ref"} and "MatchIt" package in R software were adopted to perform PSM analysis.

2.5. Statistical analysis {#cam43119-sec-0012}
-------------------------

The independent sample *t* test, Mann‐Whitney *U* test, and chi‐square test were used to compare the continuous and categorical variables, respectively. The survival differences in terms of OS and PFS were compared by the log‐rank test and survival curves were analyzed using the Kaplan‐Meier method. Prognostic factors of survival and the associated corresponding 95% confidence intervals (CIs) were determined by multivariate analyses using the Cox regression model. Statistical significance was considered when two‐tailed *P* value \< .05 was obtained. All statistical analyses were performed using R software version 3.4.2 software (R Foundation for Statistical Computing, Vienna, Austria).

3. RESULTS {#cam43119-sec-0013}
==========

3.1. Patient {#cam43119-sec-0014}
------------

A total of 75 consecutive LAPC patients were identified to have IRE or RFA after the induction chemotherapy. Among this cohort, 8 patients were excluded due to other treatments other than IRE or RFA. Additional patients were excluded due to metastatic diseases developed after the induction chemotherapy (n = 5), a history of second primary malignant tumors (n = 3), or a history of heart arrhythmia (n = 1). After the exclusion process, there were 58 patients available for analysis (IRE: 36 and RFA: 22). The baseline characteristics of patients allocated to IRE or RFA were described in Table [1](#cam43119-tbl-0001){ref-type="table"}. Patients in the IRE group were likely to have tumors located in the head of pancreas while tumors with tumor‐node‐metastasis (TNM) stage III was a little more frequently observed in patients in this group. After PSM analyses, 36 patients in the IRE group and 18 patients in the RFA group were matched and compared. FOLFIRINOX‐ and Gem‐based chemotherapy were applied to 21 (58.3%) and 15 (41.7%) patients in the IRE group, which was similar with that of the RFA group. All other factors were balanced between two groups after PSM analysis.

###### 

Comparisons of clinical and imaging characteristics of patients

  Characteristic                                             Before PSM   After PSM                                                                    
  ---------------------------------------------------------- ------------ ----------- ----------- ----------- ----------- ----------- ----------- ---- ------
  Total number                                                            36 (62.1)   22 (37.9)   58                      36 (66.7)   18 (33.3)   54   
  Age (y)[^a^](#cam43119-note-0004){ref-type="fn"}           ≤60          20 (69.0)   9 (31.0)    29          .417        20 (74.1)   7 (25.9)    27   .387
  \>60                                                       16 (55.2)    13 (44.8)   29          16 (59.3)   11 (40.7)   27                           
  Gender[^a^](#cam43119-note-0004){ref-type="fn"}            Female       19 (67.9)   9 (32.1)    28          .427        19 (67.9)   9 (32.1)    28   .847
  Male                                                       17 (56.7)    13 (43.3)   30          17 (65.4)   9 (34.6)    26                           
  Tumor size[^a^](#cam43119-note-0004){ref-type="fn"} (cm)   ≤2           1 (100.0)   0 (0.0)     1           .505        1 (100.0)   0 (0.0)     1    .685
  2 \~ 4                                                     20 (66.7)    10 (33.3)   30          20 (69.0)   9 (31.0)    29                           
  \>4                                                        15 (55.6)    12 (44.4)   27          15 (62.5)   9 (37.5)    24                           
  Tumor grade[^a^](#cam43119-note-0004){ref-type="fn"}       Well         3 (60.0)    2 (40.0)    5           .994        3 (60.0)    2 (40.0)    5    .908
  Moderate                                                   20 (62.5)    12 (37.5)   32          20 (69.0)   9 (31.0)    29                           
  Poor                                                       13 (61.9)    8 (38.1)    21          13 (65.0)   7 (35.0)    20                           
  LN metastasis                                              Absent       9 (52.9)    8 (47.1)    17          .387        9 (60.0)    6 (40.0)    15   .536
  Present                                                    27 (65.9)    14 (34.1)   41          27 (69.2)   12 (30.8)   39                           
  Tumor site[^a^](#cam43119-note-0004){ref-type="fn"}        Head         18 (64.3)   10 (35.7)   28          .018        18 (64.3)   10 (35.7)   28   .207
  Body                                                       15 (78.9)    4 (21.1)    19          15 (78.9)   4 (21.1)    19                           
  Tail                                                       3 (27.3)     8 (72.7)    11          3 (42.9)    4 (57.1)    7                            
  TNM stage[^a^](#cam43119-note-0004){ref-type="fn"}         IIB          4 (30.8)    9 (69.2)    13          .020        4 (40.0)    6 (60.0)    10   .067
  III                                                        32 (71.1)    13 (28.9)   45          32 (72.7)   12 (27.3)   44                           
  WBC (\*10^9^)                                              ≤10          32 (61.5)   20 (38.5)   52          .589        32 (66.7)   16 (33.3)   48   .687
  \>10                                                       4 (66.7)     2 (33.3)    6           4 (66.7)    2 (33.3)    6                            
  HGB (g/L)                                                  ≤120         1 (50.0)    1 (50.0)    2           .619        1 (50.0)    1 (50.0)    2    .560
  \>120                                                      35 (62.5)    21 (37.5)   56          35 (67.3)   17 (32.7)   52                           
  PLT (\*10^9^)                                              ≤300         31 (60.8)   20 (39.2)   51          .698        31 (64.6)   17 (35.4)   48   .651
  \>300                                                      5 (71.4)     2 (28.6)    7           5 (83.3)    1 (16.7)    6                            
  ALT (U/L)                                                  ≤40          26 (66.7)   13 (33.3)   39          .390        26 (70.3)   11 (29.7)   37   .536
  \> 40                                                      10 (52.6)    9 (47.4)    19          10 (58.8)   7 (41.2)    17                           
  AST (U/L)                                                  ≤ 40         29 (63.0)   17 (37.0)   46          .752        29 (67.4)   14 (32.6)   43   .537
  \>40                                                       7 (58.3)     5 (41.7)    12          7 (63.6)    4 (36.4)    11                           
  ALP (U/L)                                                  ≤100         19 (61.3)   12 (38.7)   31          .556        19 (65.5)   10 (34.5)   29   .539
  \>100                                                      17 (63.0)    10 (37.0)   27          17 (68.0)   18 (72.0)   25                           
  GGT (U/L)                                                  ≤45          19 (70.4)   8 (29.6)    27          .283        19 (73.1)   7 (26.9)    26   .395
  \>45                                                       17 (54.8)    14 (45.2)   31          17 (60.7)   11 (39.3)   28                           
  ALB (g/L)                                                  ≤ 40         4 (44.4)    5 (55.6)    9           .278        4 (50.0)    4 (50.0)    8    .418
  \>40                                                       32 (65.3)    17 (34.7)   49          32 (69.6)   14 (30.4)   46                           
  TBIL (µmol/L)                                              ≤20.5        27 (61.4)   17 (38.6)   44          .553        27 (67.5)   13 (32.5)   40   .536
  \>20.5                                                     9 (64.3)     5 (35.7)    14          9 (64.3)    5 (35.7)    14                           
  IBIL (µmol/L)                                              ≤15          32 (62.7)   19 (37.3)   51          .540        32 (68.1)   15 (31.9)   47   .674
  \>15                                                       4 (57.1)     3 (42.9)    7           4 (57.1)    3 (42.9)    7                            
  CRP (ng/L)                                                 ≤3           24 (64.9)   13 (35.1)   37          .585        24 (64.9)   13 (35.1)   37   .763
  \>3                                                        12 (57.1)    9 (42.9)    21          12 (70.6)   5 (29.4)    17                           
  CEA (ng/mL)[^a^](#cam43119-note-0004){ref-type="fn"}       ≤5           21 (70.0)   9 (30.0)    30          .250        21 (72.4)   8 (27.6)    29   .378
  \>5                                                        15 (53.6)    13 (46.4)   28          15 (60.0)   10 (40.0)   25                           
  CA19‐9 (U/mL)[^a^](#cam43119-note-0004){ref-type="fn"}     ≤35          9 (60.0)    6 (40.0)    15          .501        9 (64.3)    5 (35.7)    14   .536
  \>35                                                       27 (62.8)    16 (37.2)   43          27 (67.5)   13 (32.5)   40                           
  HBsAg                                                      Negative     33 (62.3)   20 (37.7)   53          .635        33 (66.0)   17 (34.0)   50   .593
  Positive                                                   3 (60.0)     2 (40.0)    5           3 (75.0)    1 (25.0)    4                            
  Chemotherapy                                               FOLFIRINOX   21 (67.7)   10 (32.3)   31          .420        21 (72.4)   8 (27.6)    29   .394
  Gem                                                        15 (55.6)    12 (44.4)   27          15 (60.0)   10 (40.0)   25                           

Abbreviations: ALB, albumin; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; CRP, C‐reactive protein; GGT, glutamyl transpeptidase; HBsAg, hepatitis B surface antigen; HBsAg, hepatitis B surface antigen; IBIL, indirect bilirubin; LN, lymph node metastasis; PLT, platelet count; TBIL, total bilirubin; TNM, tumor‐node‐metastasis stage; WBC, white blood cell count.

Variables that were used for propensity score matching analysis.
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3.2. Survival and tumor progression analysis {#cam43119-sec-0015}
--------------------------------------------

The whole study cohort was regularly followed up at a median time of 10.0 months (range 1.2‐75.0 months). The 1‐ and 2‐year OS rates were 60.7% and 42.5%, respectively. A total of 7 (19.4%) deaths and 11 (61.1%) deaths were observed in the IRE and RFA groups, respectively (*P* = .005). Before PSM analysis, the 1‐ and 2‐year OS rates for patients in the IRE and RFA groups were 71.4%, 53.5% and 41.3%, 30.8%, respectively (*P* = .013, Figure [1A](#cam43119-fig-0001){ref-type="fig"}). After PSM analysis, patients in the IRE group still had significant higher OS rates than those in the RFA group (1‐year OS, 71.4% vs 40.5%; 2‐year OS, 53.5% vs 27.0%; *P* = .010, Figure [1B](#cam43119-fig-0001){ref-type="fig"}).

![The Kaplan‐Meier survival curves of overall survival stratified by treatment strategies for patients with LAPC before (A) and after (B) propensity score matching](CAM4-9-4699-g001){#cam43119-fig-0001}

Tumor progression was recorded in 17 (47.2%) and 15 (83.3%) patients in the IRE and RFA groups, respectively (*P* = .018). Local recurrences were observed in 6 (16.6%) patients in the IRE group and 5 (27.7%) patients in the RFA group. In terms of distant metastases, patients in the RFA group have more cases (n = 10, 55.5%) than those in IRE group (n = 11, 30.5%). The 1‐ and 2‐year PFS rates for patients in the IRE and RFA groups were 28.4% and 28.4%, and 30.3% and 12.1%, respectively (*P* = .043, Figure [2A](#cam43119-fig-0002){ref-type="fig"}) before PSM analysis while after PSM analysis, 1‐ and 2‐year PFS rates for patients in the IRE and RFA groups were 28.4% and 28.4%, and 25.7% and 6.4%, respectively (*P* = .018, Figure [2B](#cam43119-fig-0002){ref-type="fig"}).

![The Kaplan‐Meier survival curves of progression‐free survival stratified by treatment strategies for patients with LAPC before (A) and after (B) propensity score matching](CAM4-9-4699-g002){#cam43119-fig-0002}

Tumor size was an important factor which may have an effect on the efficacy of ablation therapy. Four centimeter was adopted as the cutoff value of tumor size in this study. Fifteen (41.7%) patients and 9 (50%) patients had tumors which were larger than 4 cm in the IRE and RFA groups, respectively. For cases with LAPC larger than 4 cm, long‐term OS (*P* = .675, Figure [3A](#cam43119-fig-0003){ref-type="fig"}) and PFS (*P* = .098, Figure [3B](#cam43119-fig-0003){ref-type="fig"}) rates were similar between two groups. However, patients whose tumor sizes were smaller than 4 cm had significantly higher OS rates in the IRE group than those in the RFA group (*P* \< .001, Figure [4A](#cam43119-fig-0004){ref-type="fig"}). In addition, the survival benefit for PFS were also different between two groups, although the difference was not significant (*P* = .080, Figure [4B](#cam43119-fig-0004){ref-type="fig"}).

![The Kaplan‐Meier survival curves of overall survival (A) and progression‐free survival (B) stratified by treatment strategies for LAPC patients whose tumor was larger than 4 cm](CAM4-9-4699-g003){#cam43119-fig-0003}

![The Kaplan‐Meier survival curves of overall survival (A) and progression‐free survival (B) stratified by treatment strategies for LAPC patients whose tumor was smaller than 4 cm](CAM4-9-4699-g004){#cam43119-fig-0004}

3.3. Prognostic factors associated with OS and PFS {#cam43119-sec-0016}
--------------------------------------------------

As shown in Table [2](#cam43119-tbl-0002){ref-type="table"}, univariate analysis revealed that IRE treatment, tumor grade, ALB, and CRP were associated with OS. Moreover, multivariate analysis identified several independent prognostic factors, including chemotherapy followed by IRE treatment (HR = 4.120; 95% CI, 1.493‐11.371; *P* = .006) and ALB level (HR = 0.240, 95% CI, 0.074‐0.780, *P* = .018). For PFS analysis, the only factor identified by univariate and multivariate analyses was IRE treatment (IRE vs RFA, HR = 2.330; 95% CI, 1.138‐4.768; *P* = .021) (Table [3](#cam43119-tbl-0003){ref-type="table"}).

###### 

Univariate and multivariate analyses of OS in patients

  Characteristic      Before PSM             After PSM                                                                                                          
  ------------------- ---------------------- ----------- ------------- ------ ------- -------------- ------ ------- ------------- ------ ------- -------------- ------
  Age (y)             ≤60/ \>60              1.408       0.565‐3.508   .462                          NI     1.155   0.455‐2.933   .761                          NI
  Gender              Female/ Male           1.515       0.596‐3.851   .383                          NI     1.529   0.592‐3.951   .380                          NI
  Tumor size (cm)     ≤2/2 \~ 4/\>4          0.927       0.394‐2.180   .861                          NI     1.109   0.458‐2.687   .818                          NI
  Tumor grade         Well/ Moderate/ Poor   2.921       1.259‐6.774   .013   2.715   1.121‐6.575    .027   2.574   1.114‐5.949   .027   2.162   0.894‐5.227    .087
  LN metastasis       Absent/ Present        2.551       0.741‐8.787   .138                          NI     2.563   0.737‐8.916   .139                          NI
  Tumor site          Head/ Body/ Tail       1.151       0.629‐2.103   .649                          NI     1.170   0.608‐2.249   .638                          NI
  WBC (\*10^9^)       ≤10/ \>10              1.642       0.477‐5.651   .432                          NI     1.662   0.480‐5.761   .423                          NI
  HGB (g/L)           ≤120/ \>120            0.556       0.073‐4.221   .570                          NI     0.540   0.071‐4.119   .552                          NI
  PLT (\*10^9^)       ≤300/ \>300            0.898       0.260‐3.105   .865                          NI     1.269   0.357‐4.512   .712                          NI
  ALT (U/L)           ≤40/ \>40              0.760       0.287‐2.016   .581                          NI     0.697   0.247‐1.966   .495                          NI
  AST (U/L)           ≤40/ \>40              1.466       0.484‐4.440   .499                          NI     1.059   0.305‐3.671   .929                          NI
  ALP (U/L)           ≤100/ \>100            0.900       0.361‐2.244   .822                          NI     0.864   0.334‐2.233   .763                          NI
  GGT (U/L)           ≤45/ \>45              1.205       0.488‐2.973   .686                          NI     1.218   0.482‐3.075   .676                          NI
  ALB (g/L)           ≤40/ \>40              0.167       0.060‐0.467   .001   0.189   0.062‐0.581    .004   0.200   0.068‐0.593   .004   0.240   0.074‐0.780    .018
  TBIL (µmol/L)       ≤20.5/ \>20.5          0.661       0.192‐2.270   .511                          NI     0.656   0.190‐2.268   .505                          NI
  IBIL (µmol/L)       ≤15/ \>15              1.270       0.288‐5.598   .752                          NI     1.318   0.297‐5.853   .716                          NI
  CRP (ng/L)          ≤3/ \>3                2.613       1.047‐6.519   .039   1.384   0.511‐3.746    .523   3.127   1.185‐8.250   .021   1.848   0.603‐5.662    .282
  CEA (ng/mL)         ≤5/ \>5                1.488       0.556‐3.979   .429                          NI     1.674   0.626‐4.476   .304                          NI
  CA19‐9 (U/ml)       ≤35/ \>35              1.967       0.643‐6.020   .236                          NI     2.103   0.684‐6.468   .195                          NI
  HBsAg               Negative/ Positive     0.882       0.116‐6.686   .903                          NI     0.908   0.119‐6.918   .926                          NI
  Group               IRE/ RFA               3.151       1.220‐8.140   .018   3.870   1.426‐10.503   .008   3.320   1.264‐8.718   .015   4.120   1.493‐11.371   .006
  Chemotherapy type   FOLFIRINOX/ Gem        0.812       0.508‐1.299   .385                          NI     0.729   0.445‐1.192   .208                          NI

Abbreviations: ALB, albumin; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; CRP, C‐reactive protein; GGT, glutamyl transpeptidase; HBsAg, hepatitis B surface antigen; HBsAg, hepatitis B surface antigen; IBIL, indirect bilirubin; LN, lymph node metastasis; PLT, platelet count; TBIL, total bilirubin; TNM, tumor‐node‐metastasis stage; WBC, white blood cell count.

John Wiley & Sons, Ltd

###### 

Univariate and multivariate analyses of PFS in patients

  Characteristic      Before PSM             After PSM                                                                                                          
  ------------------- ---------------------- ----------- ------------- ------ ------- ------------- ------- ------- ------------- ------- ------- ------------- -------
  Age (years)         ≤60/ \>60              1.142       0.572‐2.279   .707                         NI      0.927   0.457‐1.884   .835                          NI
  Gender              Female/ Male           1.448       0.722‐2.902   .297                         NI      1.650   0.803‐3.390   .173                          NI
  Tumor size (cm)     ≤2/ 2 \~ 4/ \>4        0.950       0.497‐1.815   .876                         NI      1.141   0.587‐2.215   .697                          NI
  Tumor grade         Well/ Moderate/ Poor   1.232       0.691‐2.199   .480                         NI      1.098   0.619‐1.950   .749                          NI
  LN metastasis       Absent/ Present        1.434       0.645‐3.189   .376                         NI      1.444   0.646‐3.226   .370                          NI
  Tumor site          Head/ Body/ Tail       0.973       0.613‐1.545   .909                         NI      1.077   0.653‐1.776   .771                          NI
  WBC (\*10^9^)       ≤10/ \>10              1.560       0.592‐4.109   .369                         NI      1.542   0.583‐4.078   .383                          NI
  HGB (g/L)           ≤120/ \>120            0.515       0.122‐2.180   .367                         NI      0.520   0.122‐2.205   0.375                         NI
  PLT (\*10^9^)       ≤300/ \>300            0.434       0.132‐1.427   .169                         NI      0.604   0.181‐2.011   .411                          NI
  ALT (U/L)           ≤40/ \>40              0.800       0.380‐1.683   .557                         NI      0.832   0.384‐1.803   .642                          NI
  AST (U/L)           ≤40/ \>40              1.275       0.553‐2.943   .569                         NI      1.025   0.421‐2.495   .956                          NI
  ALP (U/L)           ≤100/ \>100            0.578       0.284‐1.175   .130                         NI      0.578   0.279‐1.200   .142                          NI
  GGT (U/L)           ≤45/ \>45              0.606       0.300‐1.225   .163                         NI      0.635   0.309‐1.303   .216                          NI
  ALB (g/L)           ≤40/ \>40              0.392       0.165‐0.930   .034   0.372   0.156‐0.888   0.026   0.471   0.189‐1.175   .107                          NI
  TBIL (µmol/L)       ≤20.5/ \>20.5          0.594       0.243‐1.453   .254                         NI      0.544   0.220‐1.345   .187                          NI
  IBIL (µmol/L)       ≤ 5/ \>15              1.580       0.603‐4.137   .352                         NI      1.556   0.592‐4.088   .370                          NI
  CRP (ng/L)          ≤3/ \>3                0.975       0.461‐2.062   .946                         NI      1.120   0.512‐2.450   .777                          NI
  CEA (ng/mL)         ≤5/ \>5                1.312       0.638‐2.699   .460                         NI      1.487   0.724‐3.053   .280                          NI
  CA19‐9 (U/ml)       ≤35/ \>35              1.735       0.749‐4.021   .199                         NI      1.846   0.794‐4.291   .155                          NI
  HBsAg               Negative/ Positive     1.258       0.380‐4.164   .707                         NI      1.230   0.371‐4.082   .735                          NI
  Group               IRE/ RFA               2.041       1.009‐4.129   .047   2.125   1.043‐4.330   0.038   2.330   1.138‐4.768   .021    2.330   1.138‐4.768   0.021
  Chemotherapy type   FOLFIRINOX/ Gem        1.084       0.769‐1.530   .644                         NI      1.014   0.716‐1.438   .936                          NI

Abbreviations: ALB, albumin; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; CRP, C‐reactive protein; GGT, glutamyl transpeptidase; HBsAg, hepatitis B surface antigen; HBsAg, hepatitis B surface antigen; IBIL, indirect bilirubin; LN, lymph node metastasis; PLT, platelet count; TBIL, total bilirubin; TNM, tumor‐node‐metastasis stage; WBC, white blood cell count.
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3.4. Complications comparison {#cam43119-sec-0017}
-----------------------------

As shown in Table [4](#cam43119-tbl-0004){ref-type="table"}. No intra‐abdominal hemorrhage after treatment was observed in both groups. Drainage of seroperitoneum was conducted in one patient in the IRE group and two patients in the RFA group. In addition, acute pancreatitis occurred in two patients in the RFA group while no cases occurred in the IRE group. In terms of minor complications, fever and pain were the most common complications in both groups. Significantly more cases in the RFA group (9 of 18 patients) had fever than those in the IRE group (4 of 36 patients) while similar proportions of patients in both groups had pain after treatment and required analgesics. Notably, more patients in the RFA group had vomiting (4 of 18 patients) than those in IRE group (1 of 36 patients). All patients with complications received appropriate therapy and reached the discharge criteria.

###### 

Procedure‐related complications

  Variables                               Before PSM   After PSM                    
  --------------------------------------- ------------ ----------- ------ ---- ---- ------
  Major complications                     2            7                  2    7    
  Seroperitoneum (require drainage)       1            2           .551   1    2    .255
  Acute pancreatitis                      0            2           .140   0    2    .107
  Abdominal infection                     1            3           .148   1    3    .103
  Minor complications                     24           37                 24   33   
  Fever (axillary temperature \> 38.5℃)   4            11          .002   4    9    .005
  Pain (requiring analgesics)             23           18          .234   23   16   .062
  Diarrhea                                2            3           .357   2    3    .319
  Vomiting                                1            4           .063   1    4    .038
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4. DISCUSSION {#cam43119-sec-0018}
=============

Locally advanced pancreatic cancer, a devastating disease, owns relatively high mortalities and extremely low long‐term survival rates.[^27^](#cam43119-bib-0027){ref-type="ref"}, [^28^](#cam43119-bib-0028){ref-type="ref"} IRE and RFA can be used as local ablation methods after the induction chemotherapy for patients with LAPC, while the comparison of treatment efficacy of IRE and RFA remains unclear. The present study showed that although patients in the IRE group were associated with more advanced TNM stages, IRE was superior to RFA with respect to 1‐ and 2‐year OS and PFS for all patients and those whose tumor sizes were smaller than 4 cm. The survival differences were even more obvious when the baseline factors were balanced between two groups.

As a local thermal ablative method, RFA generates local high temperatures through the high‐frequency alternating current, leading to coagulative necrosis and protein denaturation inside neoplastic tissue.[^22^](#cam43119-bib-0022){ref-type="ref"} The efficacy is partly limited by the heat sink effect in the heavily vascularized pancreas. Heat was dissipated by the blood vessels near ablation probes, leading to an area of lower temperature of the neighboring tumor cells.[^29^](#cam43119-bib-0029){ref-type="ref"}, [^30^](#cam43119-bib-0030){ref-type="ref"} Moreover, during the procedure of RFA, temperatures higher than 90℃ could induce thermal injuries and the injuries will increase with the elevation of temperatures. Therefore, the whole tumor ablation usually is avoided. The procedures of pull‐backs of the tips left a "security ring" at the periphery of the tumor, preventing high temperature diffusing to healthy surrounding tissues.[^29^](#cam43119-bib-0029){ref-type="ref"}, [^31^](#cam43119-bib-0031){ref-type="ref"} Therefore, to some extent, RFA can hardly achieve complete ablation in PDAC.[^32^](#cam43119-bib-0032){ref-type="ref"} The incomplete ablation would result in rapid local recurrence and decreased long‐term survival. In contrast, relying on the application of short and high‐voltage current pulses through the tumor, IRE causes irreversible permeabilization in cell membrane integrity and induces subsequent apoptosis.[^33^](#cam43119-bib-0033){ref-type="ref"} Therefore, IRE is not affected by the heat sink effect. The use of multiple needles allows bracketing the artery and leads to negligible amount of heat. Therefore, whole tumor can be surrounded by electric field of extremely high voltage without harming nearby important structure around pancreas.[^22^](#cam43119-bib-0022){ref-type="ref"} Therefore, the application of IRE seems to be more appropriate than RFA for PDAC, which is characterized by encapsulating celiac axis or superior mesenteric artery. In addition, by disrupting the dense stroma of LAPC and reconstruction of microcirculation,[^34^](#cam43119-bib-0034){ref-type="ref"} IRE contributed to the chemotherapy delivery to tumor, which also partly explained the survival benefit of IRE combined with systemic chemotherapy in patients with LAPC. Additionally, compared to other thermal ablative methods, IRE owns the nonthermal feature, which ensures the clinical effect is free of heat sink effect and leaves the supporting tissue largely unaffected. Considering the nature of preservation of vessels which is helpful for the transmission of immune molecules or cells, IRE may be more immunological sensitive than thermal ablations. Robert et al had shown that greater immune effect and therapeutic efficacy caused by IRE therapy in immunocompetent mice were observed than those in immunodeficient models, indicating that IRE could induce a systemic response beyond the targeted ablation region.[^35^](#cam43119-bib-0035){ref-type="ref"} Previous studies have illustrated the immune‐stimulation effect induced by IRE was helpful for the survival elevation,[^36^](#cam43119-bib-0036){ref-type="ref"}, [^37^](#cam43119-bib-0037){ref-type="ref"}, [^38^](#cam43119-bib-0038){ref-type="ref"} which would also act as the reason why IRE could work better than RFA in improving survival in LAPC patients.

A summary of studies which included a total of 106 LAPC patients after RFA treatment showed that the median postoperative complication rate and mortality were 28.3% and 7.5%, respectively.[^32^](#cam43119-bib-0032){ref-type="ref"} The median survival was 6.5 months in that study, which was similar with that of our results. In this study, LAPC patients who were treated with IRE combined with induction chemotherapy had a median OS of 21.6 months, which was in accordance with the results from study of the largest cohort conducted by Martin et al[^39^](#cam43119-bib-0039){ref-type="ref"} Moreover, Martin et al also reported a median PFS of 12.4 months, which was higher than that of our study. However, radical resection and margin accentuation by IRE were applied in nearly a quarter of all patients while our study only focused on LAPC patients who were not candidates for surgical resection. Similar with other study which showed that IRE could reduce local recurrence by allowing increased drug delivery to the tissue in the reversible electroporation zone,[^40^](#cam43119-bib-0040){ref-type="ref"} IRE combined with chemotherapy, as a kind of multidiscipline approaches, could contribute to the elevated PFS rates. In this study, the median PFS was 7.7 months for patients in the IRE group, which was significantly longer than that of patients in the RFA group. Therefore, across‐study comparisons of long‐term survival consolidated the survival benefit of IRE over RFA for patients with LAPC. Moreover, it was reported that the complication rate and mortality of IRE were 29% and 2%, respectively,[^39^](#cam43119-bib-0039){ref-type="ref"}, [^41^](#cam43119-bib-0041){ref-type="ref"} indicating that compared with RFA, IRE was a more feasible and safe local ablation method.

In addition, the prognostic factors for patients with LAPC were explored and it was found that compared with IRE, RFA contributed to better OS and PFS. Also, low albumin level was an unfavorable prognostic factor for OS and PFS, whereas poorly differentiated tumor were negative prognostic factor for OS, consistent with results from previous studies.[^42^](#cam43119-bib-0042){ref-type="ref"}, [^43^](#cam43119-bib-0043){ref-type="ref"} Interestingly, when subgroup analyses stratified by tumor size were conducted, it was shown that patients had similar OS and PFS rates in both the IRE and RFA groups if tumor sizes were larger than 4 cm; although IRE displayed better in elevated long‐term survival rates in all patients or patients whose tumor sizes were smaller than 4 cm. Compared with a single ablation, multiple overlapping ablations may partly enlarge the possible ablation area and shrink the "security ring" around the tumor. Moreover, due to the presence of viable "security ring" of RFA at the periphery of tumor, the addition of IRE targeted at this area will make a complete ablation. Therefore, combining the advantages of IRE and RFA, it was suggested that maybe the combination of RFA ablation followed by tumor margin accentuation by IRE was a feasible local destructive method for the treatment of patients with LAPC. However, more appropriate randomized controlled studies are needed to evaluate the feasibility and efficacy of this new combination therapy.

There were several limitations which should be considered. The small sample size of patients and the potential patient selection bias kept us from drawing definitive conclusions. To improve the intergroup comparability, PSM analysis was applied to reduced selection bias. Large‐scale prospective randomized controlled studies are warranted to confirm results of this study.

In conclusion, it was the first time to show that compared with RFA, IRE resulted in better survival after the induction chemotherapy in LAPC patients and should be considered as the first‐line ablation modality. The efficacy of the combination therapy of IRE and induction chemotherapy is needed to be confirmed by randomized clinical trials.
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